| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 8.0 | 5.5 |
| Gross profit | 3.6 | 2.4 |
| Profit before tax | 0.9 | -0.1 |
| Net income | 1.0 | -0.1 |
| EPS (diluted, $ a share) | $0.10 | $-0.02 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +46.0% |
|---|---|
| Gross margin | 44.2% |
| Operating margin | 11.9% |
10-Q filed with the SEC, NASDAQ: ICCC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Immucell Corp: key numbers
- Share price
- $11.42Close, Nov 16
- Market cap
- $104M
- Shares outstanding
- 9.09MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Immucell Corp
All →Immucell Financial Results
ImmuCell reported Q3 2026 financial results with revenue growing 46% to $8.0 million and net income of $953,000. The company highlighted broad-based growth across sales territories and announced the termination of its At-The-Market (ATM) offering program due to a strong cash position.
- Term
- Q3 2026
“ImmuCell had a strong quarter. The expanded commercial team is delivering solid revenue growth as we reach more customers with our value propositions. Increased commercial activity was supported by increased output from the manufacturing team. We are investing in capacity expansion and colostrum sourcing capabilities for future demand, and those efforts are projected to be completed on time and within budget.”
Olivier te Boekhorst, President and CEO
“Today we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025. Revenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part by the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025.”
Timothy C. Fiori, Chief Financial Officer
Immucell Business Update
ImmuCell Corporation announced preliminary, unaudited sales results for the third quarter of 2026, reporting total sales of $8.0 million, a 46% increase over the same period in 2025. The growth was driven by strong performance across its product portfolio, including a 51% increase in Tri-Shield sales and a 27.8% increase in total sales for the first nine months of the year.
- Term
- Q3 2026